You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

68Ga-DOTA-TATE

Showing 1 - 25 of 529
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumors Trial in Sherbrooke (68Ga-DOTA-TATE)

Recruiting
  • Neuroendocrine Tumors
  • 68Ga-DOTA-TATE
  • Sherbrooke, Quebec, Canada
    CHUS
Jul 18, 2022

Ganglioneuroblastoma, Ganglioneuroma, Metastatic Neuroblastoma Trial in Rochester (Computed Tomography, Gallium Ga 68-DOTATATE,

Recruiting
  • Ganglioneuroblastoma
  • +2 more
  • Computed Tomography
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 30, 2023

Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma Trial in Rochester (radiation, drug, procedure, other)

Recruiting
  • Grade 1 Meningioma
  • +4 more
  • Gallium Ga 68-DOTATATE
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 11, 2023

Meningioma Trial in Houston (Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography)

Recruiting
  • Meningioma
  • Computed Tomography
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 28, 2022

Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor

Recruiting
  • PET / CT
  • +3 more
  • 68Ga-DOTA-TATE PET/MR and PET/CT imaging
  • Wuhan, Hubei, China
    China, Hubei Province
Apr 26, 2022

Neuroendocrine Tumors Trial in Sherbrooke (Gallium-68 DOTA TATE PET scan)

Completed
  • Neuroendocrine Tumors
  • Gallium-68 DOTA TATE PET scan
  • Sherbrooke, Quebec, Canada
    Centre hospitalier universitaire de Sherbrooke
May 17, 2021

Glioblastoma Trial in France, Portugal, Spain ([177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide)

Recruiting
  • Glioblastoma
  • Bron, France
  • +8 more
Jan 23, 2023

Extensive Stage Small Cell Lung Cancer Trial in France ([177Lu]Lu-DOTA-TATE, Tislelizumab, [68Ga]Ga-DOTA-TATE)

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • Lille, France
  • +6 more
Jan 23, 2023

Tumor-Induced Osteomalacia Trial in Beijing (68Ga-Dotatate, 68Ga-DOTA-JR11)

Recruiting
  • Tumor-Induced Osteomalacia
  • Beijing, Dongcheng, China
    Peking union medical college hospital
Jan 2, 2021

Neuroendocrine Tumors Trial in Innsbruck (68Ga-DOTA-MGS5)

Completed
  • Neuroendocrine Tumors
  • Innsbruck, Austria
    Department of Nuclear Medicine, Medical University of Innsbruck
Nov 24, 2023

Cancer Diagnosis, Diagnostic Techniques and Procedures, Diagnostic Imaging Trial in Palo Alto (F-18 FDG, Ga-68-DOTA-TATE,

Completed
Has Results
  • Cancer Diagnosis
  • +2 more
  • F-18 FDG
  • +3 more
  • Palo Alto, California
    Stanford University, School of Medicine
Apr 8, 2021

Tumor Positron-Emission Tomography Trial in Fuzhou (68Ga-DOTATATE and 68Ga-FAPI)

Recruiting
  • Tumor Positron-Emission Tomography
  • 68Ga-DOTATATE and 68Ga-FAPI
  • Fuzhou, Fujian, China
    Department of Nuclear Medicine, First Affiliated Hospital of Fuj
Aug 7, 2023

Tumor, Solid Trial in Beijing (68Ga-DOTA-F2 PET/CT and 18F-FDG)

Recruiting
  • Tumor, Solid
  • 68Ga-DOTA-F2 PET/CT and 18F-FDG
  • Beijing, Beijing, China
    Peking union medical college hospital
Nov 27, 2022

Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma Trial in Sacramento ([68Ga]Ga DOTA-5G and [177Lu]Lu

Recruiting
  • Metastatic Pancreatic Cancer
  • Locally Advanced Pancreatic Adenocarcinoma
  • [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
  • Sacramento, California
    University of California Davis
Apr 21, 2022

Nasopharyngeal Carcinoma Trial in Xiamen (177Lu-EB-LM3 1, 177Lu-EB-LM3 2)

Recruiting
  • SSTR2-positive Tumors
  • 177Lu-LNC1010 1
  • +2 more
  • Xiamen, China
    The First Affiliated Hospital of Xiamen University
Nov 20, 2022

Tumor, Solid Trial in Xiamen (68Ga-DOTA-hLAG-3 PET/CT)

Recruiting
  • Tumor, Solid
  • 68Ga-DOTA-hLAG-3 PET/CT
  • Xiamen, Fujian, China
    The First affiliated hospital of xiamen university
May 8, 2022

PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9

Enrolling by invitation
  • Acute Myeloid Leukemia
  • +2 more
    • Turku, Finland
      Turku University Hospital, Turku PET Centre
    May 3, 2022

    Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma Trial in Palo Alto (Gallium Ga 68 DOTA-NeoBOMB1, Gallium

    Suspended
    • Prostate Adenocarcinoma
    • +2 more
    • Gallium Ga 68 DOTA-NeoBOMB1
    • Gallium Ga 68 PSMA-R2
    • Palo Alto, California
      Stanford Cancer Institute Palo Alto
    May 3, 2022

    Lung Cancer, Neuroendocrine Tumor Trial in Beijing (68Ga-NOTA-3P-TATE-RGD)

    Recruiting
    • Lung Cancer
    • Neuroendocrine Neoplasm
    • Beijing, Beijing, China
      Peking Union Medical College Hospitall, Chinese Academy of Medic
    Mar 30, 2022

    Neuroendocrine Tumors Trial in New York (PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11)

    Completed
    Has Results
    • Neuroendocrine Tumors
    • PET/CT Imaging
    • +2 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jan 3, 2022

    Prostate Cancer Trial in Stanford (68Ga RM2, 68Ga-PSMA-11, Investigational PET scanner coils and software)

    Suspended
    • Prostate Cancer
    • 68Ga RM2
    • +2 more
    • Stanford, California
      Stanford University
    May 3, 2022

    Pancreatic Ductal Adenocarcinoma Trial in Nanjing (68Ga-DOTA-NT-20.3)

    Recruiting
    • Pancreatic Ductal Adenocarcinoma
    • 68Ga-DOTA-NT-20.3
    • Nanjing, China
      Nanjing First Hospital
    Sep 9, 2021

    Tumor, Solid, FAPI, PET/CT, Metastasis Trial in Xiamen (68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT)

    Recruiting
    • Tumor, Solid, FAPI, PET/CT, Metastasis
    • 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT
    • Xiamen, Fujian, China
      The First affiliated hospital of xiamen university
    Jun 25, 2021

    PET Imaging of Systemic Sclerosis Using FDG and

    Enrolling by invitation
    • Systemic Sclerosis
      • Turku, Finland
        Turku University Hospital, Turku PET Centre
      Nov 29, 2021

      Prostate Adenocarcinoma Trial in Palo Alto (Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Magnetic Resonance Imaging,

      Active, not recruiting
      • Prostate Adenocarcinoma
      • Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
      • +2 more
      • Palo Alto, California
        Stanford University, School of Medicine
      May 3, 2022